A Clinical Study to Evaluate the Relative Bioavailability of Enlicitide Formulations in Healthy Adult Participants
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Enlicitide decanoate (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 08 Apr 2025 Status changed from not yet recruiting to recruiting.
- 02 Apr 2025 Planned primary completion date changed from 23 May 2025 to 18 Apr 2025.
- 02 Apr 2025 Planned initiation date changed from 4 Apr 2025 to 3 Apr 2025.